SUPPLEMENTAL METHODS

MRI parameters

Pulse sequences included coronal, T1-weighted, 3-dimensional (3D) gradient-echo (flip angle 65°, repetition time [TR] 35 milliseconds, echo time [TE] 16 milliseconds, field of view 120 mm, matrix 160 × 192, slice thickness 0.6 mm, giving a voxel resolution of 750 μm × 625 μm × 600 μm; one excitation was averaged), coronal 2D short-tau inversion recovery (STIR) (inversion time 85 milliseconds, TR 1520-1960 milliseconds, TE 24 milliseconds, field of view 120 mm, matrix 144 × 192, slice thickness 3.0 mm, with an interslice gap of 0.3 mm, giving a voxel resolution of 833 μm × 625 μm × 3000 μm; 2 excitations were averaged), and axial 2D STIR (inversion time 85 milliseconds, TR 1680-2400 milliseconds, TE 24 milliseconds, field of view 120 mm, matrix 144 × 192, slice thickness 3.0 mm, with an interslice gap of 0.3 mm, giving a voxel resolution of 833 μm × 625 μm × 3000 μm; 2 excitations were averaged).
Supplemental Figure 1. Changes in radiographic Genant-modified Total Sharp Scores in patients taking tocilizumab (TCZ) 8 mg/kg plus methotrexate (MTX) or placebo (PBO) plus MTX. (A) Mean change from baseline in Total Sharp Scores at weeks 24 and 52. (B) Mean change from baseline in erosion scores at weeks 24 and 52. (C) Mean change from baseline in joint space narrowing scores at weeks 24 and 52. Error bars represent standard error of the mean (SEM).
A

Week 24  |  Week 52
---|---
TCZ + MTX: n = 28  |  n = 28
TCZ + PBO: n = 28  |  n = 24

* P = 0.6172; † P = 0.3430; ‡ P = 0.0434; § P = 0.3484 when compared with baseline.

B

Week 24  |  Week 52
---|---
TCZ + MTX: n = 28  |  n = 28
TCZ + PBO: n = 28  |  n = 24

* P = 0.7779; † P = 0.2402; ‡ P = 0.9800; § P = 0.4131 when compared with baseline.

C

Week 24  |  Week 52
---|---
TCZ + MTX: n = 28  |  n = 28
TCZ + PBO: n = 28  |  n = 24

* P = 0.0313; † P = 0.8750; ‡ P = 0.0234; § P = 0.7500 when compared with baseline.